$ISRG

Jeddi Iman sold $2.4M of ISRG

Jeddi Iman (SVP & GM da Vinci Platforms &) sold 5,625 shares of INTUITIVE SURGICAL INC (ISRG) at $420.55 ($2.37M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jeddi Iman
Published Jun 2, 2026, 2:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 2:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ISRG
Neutral
medium confidence
Mentioned
$ISRG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

Because the sale is pre-arranged, it is generally treated as lower-signal for company-specific negative news; the main tradable element is short-term sentiment/positioning.

02

Market read

A disclosed insider sale in ISRG, but with 10b5-1 framing, suggesting limited fundamental implications.

03

What to watch

Check whether this sale is part of a larger sequence of officer sales or whether other insiders are buying/selling around the same window.

Relevance 6/10Novelty 6/10Timing: Filed June 2; sale executed June 1

Background

The filing is an SEC Form 4 for an officer (SVP & GM da Vinci Platforms) reporting an open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$ISRGNeutralMedium confidence
Context

Intuitive Surgical disclosed an officer open-market sale of 5,625 shares under a pre-arranged 10b5-1 plan on June 1.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief unless follow-on selling accelerates.

Evidence & confidence

The transaction is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary sales.

Market effects

Minimal; single-company 10b5-1 sale does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution about near-term execution or valuation.

Key entities

  • Intuitive Surgical

    Subject of the Form 4 insider transaction disclosure.

  • Jeddi Iman

    Officer reporting the sale of ISRG shares.

  • Rule 10b5-1 plan

    Pre-arranged trading plan that reduces discretionary interpretation.

Related articles

$ISRGMed

UBS starts medtech coverage, favors Intuitive Surgical and Enovis By Investing.com

UBS initiated coverage of four U.S. medtech firms. It assigned Buy ratings to Intuitive Surgical (ISRG) with a $500 price target and Enovis (ENOV) with a $51 target, citing growth drivers and improving fundamentals. UBS gave Inspire Medical Systems (INSP) a Sell rating with a $39 target and Integra LifeSciences (IART) a Neutral rating with a $19 target, citing competition, reimbursement and limited catalysts.

$UNHMed

UnitedHealth Group Incorporated (UNH) and Intuitive Surgical, Inc. (ISRG) Just Showed Why Beating Estimates Isn’t Enough

UnitedHealth (UNH) and Intuitive Surgical (ISRG) both beat July earnings estimates. UNH reported adjusted EPS of $6.38 vs $4.90 expected, revenue of $112B, and raised full-year profit guidance to $19.50-$20. ISRG reported $2.89B revenue and $2.80 EPS vs $2.50 expected, but shares fell after guidance implied slower procedure growth near the middle of its range.

$ISRGMedAI 8/10

The $100 Billion Surgery Giant That Wall Street Suddenly Doesn't Trust

Intuitive Surgical reported Q2 adjusted EPS of $2.80 vs $2.50 expected and revenue of $2.89B vs $2.82B, with 468 new da Vinci systems installed and an installed base of 11,710. Shares fell over 9% after-hours and trade near the 52-week low. Guidance for 2026 was confirmed but not raised, while analysts cited ACA subsidy changes, GLP-1 impacts, and tariffs.

$JNJMedAI 8/10

Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today

Intuitive Surgical (ISRG) shares fell after Johnson & Johnson (JNJ) received U.S. FDA marketing authorization for its Ottava robotic surgical platform. The article says JNJ plans an immediate U.S. commercial rollout and faster launches in Western Europe and Japan, positioning Ottava as a competitive alternative to ISRG’s da Vinci systems. It cites ISRG down about 35% YTD and options data implying further near-term downside.